Brain Metabolic Alterations in Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 110 of the 110 references it cites were found in a registry or an index.
Abstract
The brain is one of the most energy-consuming organs in the body. Satisfying such energy demand requires compartmentalized, cell-specific metabolic processes, known to be complementary and intimately coupled. Thus, the brain relies on thoroughly orchestrated energy-obtaining agents, processes and molecular features, such as the neurovascular unit, the astrocyte–neuron metabolic coupling, and the cellular distribution of energy substrate transporters. Importantly, early features of the aging process are determined by the progressive perturbation of certain processes responsible for adequate brain energy supply, resulting in brain hypometabolism. These age-related brain energy alterations are further worsened during the prodromal stages of neurodegenerative diseases, namely Alzheimer’s disease (AD), preceding the onset of clinical symptoms, and are anatomically and functionally associated with the loss of cognitive abilities. Here, we focus on concrete neuroenergetic features such as the brain’s fueling by glucose and lactate, the transporters and vascular system guaranteeing its supply, and the metabolic interactions between astrocytes and neurons, and on its neurodegenerative-related disruption. We sought to review the principles underlying the metabolic dimension of healthy and AD brains, and suggest that the integration of these concepts in the preventive, diagnostic and treatment strategies for AD is key to improving the precision of these interventions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2013) · Cell · doi:10.1016/j.cell.2013.05.039 · Cited by 14,982 · cited 2×
“Aging is an irreversible and intricate process characterized by the time-dependent functional decline of physiological integrity [85], thereby being the main risk factor for susceptibility to neurodegenerative diseases [86].”
BackgroundSokoloff, L., Reivich, M., Kennedy, C., Rosiers, M. H. D., Patlak, C. S., Pettigrew, K. D., Sakurada, O., & Shinohara, M. (1977) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1977.tb10649.x · Cited by 6,000
Structure and function of the blood–brain barrier
Abbott, N. J., Patabendige, A. A. K., Dolman, D. E. M., Yusof, S. R., & Begley, D. J. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.030 · Cited by 5,185
Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
An Energy Budget for Signaling in the Grey Matter of the Brain
Attwell, D., & Laughlin, S. B. (2001) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200110000-00001 · Cited by 3,543
The NLRP3 Inflammasome: an overview of mechanisms of activation and regulation
Kelley, N., Jeltema, D., Duan, Y., & He, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133328 · Cited by 3,539 · cited 2×
“NAD+ has also been proposed to regulate neuroinflammation by inhibiting the major inflammasome NLRP3, a key component of the innate immune system, highly involved in AD pathology [227].”
BackgroundDaneman, R., & Prat, A. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a020412 · Cited by 3,437 · cited 1×
“Importantly, the BBB impedes the access of blood-borne immune cells, toxins and pathogens that could interfere with adequate neuronal function [25].”
BackgroundThe Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280
Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969
Pellerin, L., & Magistretti, P. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.22.10625 · Cited by 2,927 · cited 4×
“The first demonstration that glycogen metabolism may involve an astrocyte–neuron interaction was obtained by Magistretti and co-workers, who showed that the release of neurotransmitters from the neuron could induce glycogenolysis in astrocytes [79,80].”
BackgroundInfluentialInsights into the ageing mind: a view from cognitive neuroscience
Hedden, T., & Gabrieli, J. D. E. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1323 · Cited by 2,223 · cited 1×
“In contrast, other types of major cognitive functions do not decline until very advanced stages of senescence, such as semantic memory, or might even present life-long stability, such as emotional processing [90].”
BackgroundBlood-brain barrier breakdown in the aging human hippocampus
Montagne, A., Barnes, S. R., Sweeney, M. D., Halliday, M. R., Sagare, A. P., Zhao, Z., Toga, A. W., Jacobs, R. E., Liu, C. Y., Amezcua, L., et al. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.032 · Cited by 2,102 · cited 1×
“Indeed, age-induced BBB permeability is exacerbated in mild cognitive impairment or early stages of AD compared to neurologically healthy individuals [175,176], suggesting that neurovascular dysfunction is an early event in the pathogenesis of AD.”
BackgroundOxidative stress, dysfunctional glucose metabolism and Alzheimer disease
Butterfield, D. A., & Halliwell, B. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-019-0132-6 · Cited by 1,954 · cited 1×
“Conversely, abnormal protein accumulation promotes mitochondrial damage, decreases energy production and improves oxidative stress [186,202].”
BackgroundTalbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59903 · Cited by 1,871
Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease
Minoshima, S., Giordani, B., Berent, S., Frey, K. A., Foster, N. L., & Kuhl, D. E. (1997) · Annals of Neurology · doi:10.1002/ana.410420114 · Cited by 1,802
Synaptic Energy Use and Supply
Harris, J. J., Jolivet, R., & Attwell, D. (2012) · Neuron · doi:10.1016/j.neuron.2012.08.019 · Cited by 1,747
Steen, E., Terry, B. M., J. Rivera, E., Cannon, J. L., Neely, T. R., Tavares, R., Xu, X. J., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2005-7107 · Cited by 1,703
Oligodendroglia metabolically support axons and contribute to neurodegeneration
Lee, Y., Morrison, B. M., Li, Y., Lengacher, S., Farah, M. H., Hoffman, P. N., Liu, Y., Tsingalia, A., Jin, L., Zhang, P.-W., et al. (2012) · Nature · doi:10.1038/nature11314 · Cited by 1,664 · cited 1×
“Specifically, MCT1 is present in BBB endothelial cells [15], astrocytes [46], oligodendrocytes [47], and microglia [48], and shows high affinity for pyruvate, although it can also transport lactate and ketone bodies.”
BackgroundBrain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums
Arnold, S. E., Arvanitakis, Z., Macauley-Rambach, S. L., Koenig, A. M., Wang, H.-Y., Ahima, R. S., Craft, S., Gandy, S., Buettner, C., Stoeckel, L. E., et al. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.185 · Cited by 1,597
Jankowsky, J. L., Fadale, D. J., Anderson, J., Xu, G. M., Gonzales, V., Jenkins, N. A., Copeland, N. G., Lee, M. K., Younkin, L. H., Wagner, S. L., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh019 · Cited by 1,575
Uniquely Hominid Features of Adult Human Astrocytes
Oberheim, N. A., Takano, T., Han, X., He, W., Lin, J. H. C., Wang, F., Xu, Q., Wyatt, J. D., Pilcher, W., Ojemann, J. G., et al. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.4707-08.2009 · Cited by 1,488
Regulation of hepatic fatty acid oxidation and ketone body production
McGarry, J. D., & Foster, D. W. (1980) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.49.070180.002143 · Cited by 1,460 · cited 1×
“Under fasting conditions, the liver is the organ responsible for ketone body generation from fatty acids and amino acids [24].”
BackgroundLongitudinal Magnetic Resonance Imaging Studies of Older Adults: A Shrinking Brain
Resnick, S. M., Pham, D. L., Kraut, M. A., Zonderman, A. B., & Davatzikos, C. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-08-03295.2003 · Cited by 1,425 · cited 1×
“Importantly, these cognitive alterations show a close correlation with age-induced neuroanatomical changes [91].”
BackgroundPathogenesis of type 2 diabetes mellitus
DeFronzo, R. A. (2004) · Medical Clinics of North America · doi:10.1016/j.mcna.2004.04.013 · Cited by 1,342
New roles for astrocytes: redefining the functional architecture of the brain.
Nedergaard, M., Ransom, B., & Goldman, S. A. (2003) · Trends in Neurosciences · doi:10.1016/j.tins.2003.08.008 · Cited by 1,334 · cited 1×
“Within the human brain, the number of astrocytes is significantly higher than the number of neurons [52].”
BackgroundMitochondria dysfunction in the pathogenesis of Alzheimer’s disease: Recent advances.
Wang, W., Zhao, F., Ma, X., Perry, G., & Zhu, X. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00376-6 · Cited by 1,274 · cited 1×
“Neuronal mitochondrial disturbances lead to decreased ATP levels, lower glycolytic rates and increased oxidative stress, together with neuronal apoptosis [118,119].”
BackgroundHallmarks of Brain Aging: Adaptive and Pathological Modification by Metabolic States
Mattson, M. P., & Arumugam, T. V. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.05.011 · Cited by 1,242
Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease
Kivipelto, M., Mangialasche, F., & Ngandu, T. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0070-3 · Cited by 1,173
Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy
Bu, G. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2620 · Cited by 1,168
Alzheimer’s disease is type 3 diabetes—Evidence reviewed
de la Monte, S. M., & Wands, J. R. (2008) · Journal of Diabetes Science and Technology · doi:10.1177/193229680800200619 · Cited by 1,158
Glial regulation of the cerebral microvasculature
Iadecola, C., & Nedergaard, M. (2007) · Nature Neuroscience · doi:10.1038/nn2003 · Cited by 1,153 · cited 1×
“Astrocytic endfeet also express several proteins, including important transporters and channels such as GLUTs and aquaporin 4 [55].”
BackgroundPhysiological roles of ketone bodies as substrates and signals in mammalian tissues.
Robinson, A. M., & Williamson, D. H. (1980) · Physiological Reviews · doi:10.1152/physrev.1980.60.1.143 · Cited by 1,012
Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing
Cunnane, S. C., Trushina, E., Morland, C., Prigione, A., Casadesus, G., Andrews, Z. B., Beal, M. F., Bergersen, L. H., Brinton, R. D., de la Monte, S., et al. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0072-x · Cited by 1,003 · cited 2×
“Brain metab‐ olism modulation can be achieved either in a direct manner with treatments such as in‐ tranasal insulin, or indirectly, acting on peripheral metabolism with diet modifications (low‐fat, ketogenic) or insulin modulators [260].”
BackgroundFunctional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia
Reiman, E. M., Chen, K., Alexander, G. E., Caselli, R. J., Bandy, D., Osborne, D., Saunders, A. M., & Hardy, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2635903100 · Cited by 977
Exercise-linked FNDC5/irisin rescues synaptic plasticity and memory defects in Alzheimer’s models
Lourenco, M. V., Frozza, R. L., de Freitas, G. B., Zhang, H., Kincheski, G. C., Ribeiro, F. C., Gonçalves, R. A., Clarke, J. R., Beckman, D., Staniszewski, A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0275-4 · Cited by 935
Activity-driven local ATP synthesis is required for synaptic function
Rangaraju, V., Calloway, N., & Ryan, T. A. (2014) · Cell · doi:10.1016/j.cell.2013.12.042 · Cited by 836
Kellar, D., & Craft, S. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30231-3 · Cited by 832
Activity-dependent regulation of energy metabolism by astrocytes: an update
Pellerin, L., Bouzier‐Sore, A., Aubert, A., Serres, S., Merle, M., Costalat, R., & Magistretti, P. J. (2007) · Glia · doi:10.1002/glia.20528 · Cited by 805 · cited 1×
“The elevation of the glycolytic rate leads to the production of a high amount of lactate, which is subsequently released to the extracellular space and can be taken up by neurons as energy fuel for oxidative phosphorylation-derived ATP production [77,78] (Figure 1).”
BackgroundCerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer’s disease
Small, G. W., Ercoli, L. M., Silverman, D. H. S., Huang, S.-C., Komo, S., Bookheimer, S. Y., Lavretsky, H., Miller, K., Siddarth, P., Rasgon, N. L., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.090106797 · Cited by 790
Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain
Mecocci, P., MacGarvey, U., Kaufman, A. E., Koontz, D., Shoffner, J. M., Wallace, D. C., & Beal, M. F. (1993) · Annals of Neurology · doi:10.1002/ana.410340416 · Cited by 757 · cited 1×
“The presence of damaged mitochondria is a common feature in aging that correlates with the accumulation of damaged and dysfunctional organelles [85,120].”
BackgroundBrain metabolism in health, aging, and neurodegeneration
Camandola, S., & Mattson, M. P. (2017) · The EMBO Journal · doi:10.15252/embj.201695810 · Cited by 752
Brain insulin and insulin receptors in aging and sporadic Alzheimer’s disease
Frölich, L., Blum-Degen, D., Bernstein, H.-G., Engelsberger, S., Humrich, J., Laufer, S., Muschner, D., Thalheimer, A., Türk, A., Hoyer, S., et al. (1998) · Journal of Neural Transmission · doi:10.1007/s007020050068 · Cited by 748
Rivera, E. J., Goldin, A., Fulmer, N., Tavares, R., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer s Disease · doi:10.3233/jad-2005-8304 · Cited by 723
McClean, P. L., Parthsarathy, V., Faivre, E., & Hölscher, C. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0529-11.2011 · Cited by 698
GLUT1 reductions exacerbate Alzheimer's disease vasculo-neuronal dysfunction and degeneration
Winkler, E. A., Nishida, Y., Sagare, A. P., Rege, S. V., Bell, R. D., Perlmutter, D., Sengillo, J. D., Hillman, S., Kong, P., Nelson, A. R., et al. (2015) · Nature Neuroscience · doi:10.1038/nn.3966 · Cited by 689
Astrocyte glycogen and brain energy metabolism
Brown, A. M., & Ransom, B. R. (2007) · Glia · doi:10.1002/glia.20557 · Cited by 626 · cited 1×
“The importance of glycogen stores in the preservation and viability of neuronal activity upon glucose scarcity, such as hypoglycemia, also reinforces the idea of the interaction between astrocytes and neurons involving glycogen [75,81].”
BackgroundComparing predictors of conversion and decline in mild cognitive impairment
Landau, S. M., Harvey, D., Madison, C. M., Reiman, E. M., Foster, N. L., Aisen, P. S., Petersen, R. C., Shaw, L. M., Trojanowski, J. Q., Jack, C. R., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e8e8b8 · Cited by 616
Blood-Brain Barrier Leakage in Patients with Early Alzheimer Disease
van de Haar, H. J., Burgmans, S., Jansen, J. F. A., van Osch, M. J. P., van Buchem, M. A., Muller, M., Hofman, P. A. M., Verhey, F. R. J., & Backes, W. H. (2016) · Radiology · doi:10.1148/radiol.2016152244 · Cited by 601
ApoE genotype accounts for the vast majority of AD risk and AD pathology
Raber, J., Huang, Y., & Ashford, J. W. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.12.023 · Cited by 599
Epileptic activity in Alzheimer’s disease: Causes and clinical relevance
Vossel, K. A., Tartaglia, M. C., Nygaard, H. B., Zeman, A. Z., & Miller, B. L. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30044-3 · Cited by 590
A Quarter Century of APOE and Alzheimer’s Disease: Progress to Date and the Path Forward
Belloy, M. E., Napolioni, V., & Greicius, M. D. (2019) · Neuron · doi:10.1016/j.neuron.2019.01.056 · Cited by 570
Craft, S., Peskind, E., Schwartz, M. W., Schellenberg, G. D., Raskind, M., & Porte, D. (1998) · Neurology · doi:10.1212/wnl.50.1.164 · Cited by 560
Alzheimer’s disease drug development pipeline: 2020
Cummings, J., Lee, G., Ritter, A., Sabbagh, M., & Zhong, K. (2020) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12050 · Cited by 557
Age-related alterations in the dynamic behavior of microglia
Damani, M. R., Zhao, L., Fontainhas, A. M., Amaral, J., Fariss, R. N., & Wong, W. T. (2011) · Aging Cell · doi:10.1111/j.1474-9726.2010.00660.x · Cited by 504 · cited 4×
“Moreover, aged microglia show altered responses to extracellular ATP signals compared to young microglia, being less dynamic and branched during senescence [219].”
BackgroundInfluentialNAD(+) in aging: molecular mechanisms and translational implications
Fang, E. F., Lautrup, S., Hou, Y., Demarest, T. G., Croteau, D. L., Mattson, M. P., & Bohr, V. A. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.08.001 · Cited by 501
Elevated gene expression levels distinguish human from non-human primate brains
Cáceres, M., Lachuer, J., Zapala, M. A., Redmond, J. C., Kudo, L., Geschwind, D. H., Lockhart, D. J., Preuss, T. M., & Barlow, C. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2135499100 · Cited by 491
Microvascular injury and blood–brain barrier leakage in Alzheimer's disease
Zipser, B. D., Johanson, C. E., Gonzalez, L., Berzin, T. M., Tavares, R., Hulette, C. M., Vitek, M. P., Hovanesian, V., & Stopa, E. G. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.05.016 · Cited by 487
Mosconi, L., Mistur, R., Switalski, R., Tsui, W. H., Glodzik, L., Li, Y., Pirraglia, E., De Santi, S., Reisberg, B., Wisniewski, T., et al. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-1039-z · Cited by 487
Gejl, M., Gjedde, A., Egefjord, L., Møller, A., Hansen, S. B., Vang, K., Rodell, A., Brændgaard, H., Gottrup, H., Schacht, A., et al. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00108 · Cited by 480
Insulin resistance as the core defect in type 2 diabetes mellitus
Goldstein, B. J. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02553-5 · Cited by 432
Energy-Efficient Action Potentials in Hippocampal Mossy Fibers
Alle, H., Roth, A., & Geiger, J. R. P. (2009) · Science · doi:10.1126/science.1174331 · Cited by 429
Lin, B., Koibuchi, N., Hasegawa, Y., Sueta, D., Toyama, K., Uekawa, K., Ma, M., Nakagawa, T., Kusaka, H., & Kim-Mitsuyama, S. (2014) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0148-1 · Cited by 423
Selective distribution of lactate dehydrogenase isoenzymes in neurons and astrocytes of human brain
Bittar, P. G., Charnay, Y., Pellerin, L., Bouras, C., & Magistretti, P. J. (1996) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199611000-00001 · Cited by 423 · cited 1×
“Contrarily, neurons lack LDH5 and express the LDH1 subunit, which favors the formation of pyruvate from lactate [73].”
BackgroundRole of Astrocytes in Neurovascular Coupling
Petzold, G. C., & Murthy, V. N. (2011) · Neuron · doi:10.1016/j.neuron.2011.08.009 · Cited by 409
Neuronal-glial glucose oxidation and glutamatergic-GABAergic function.
Hyder, F., Patel, A. B., Gjedde, A., Rothman, D. L., Behar, K. L., & Shulman, R. G. (2006) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600263 · Cited by 408 · cited 1×
“In humans, 13C and 1H NMR studies in healthy subjects have demonstrated that neuronal mitochondrial metabolism is ~30% lower in elderly subjects compared to young [70,207].”
BackgroundThe role of astroglia in neuroprotection
Bélanger, M., & Magistretti, P. J. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.3/mbelanger · Cited by 396 · cited 1×
“of gliotransmitters (that modulate neurotransmission), synapse formation and synapse remodeling, among other processes [53,54].”
Craft, S., Raman, R., Chow, T. W., Rafii, M. S., Sun, C.-K., Rissman, R. A., Donohue, M. C., Brewer, J. B., Jenkins, C., Harless, K., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.1840 · Cited by 389
Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease
Sato, T., Hanyu, H., Hirao, K., Kanetaka, H., Sakurai, H., & Iwamoto, T. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.10.009 · Cited by 387
Lebon, V., Petersen, K. F., Cline, G. W., Shen, J., Mason, G. F., Dufour, S., Behar, K. L., Shulman, G. I., & Rothman, D. L. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01523.2002 · Cited by 371
Kashiwaya, Y., Bergman, C., Lee, J.-H., Wan, R., King, M. T., Mughal, M. R., Okun, E., Clarke, K., Mattson, M. P., & Veech, R. L. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.11.023 · Cited by 363
Hippocampal hypometabolism predicts cognitive decline from normal aging
Mosconi, L., De Santi, S., Li, J., Tsui, W. H., Li, Y., Boppana, M., Laska, E., Rusinek, H., & de Leon, M. J. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.12.008 · Cited by 360
Tramutola, A., Triplett, J. C., Di Domenico, F., Niedowicz, D. M., Murphy, M. P., Coccia, R., Perluigi, M., & Butterfield, D. A. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13037 · Cited by 347
[18F]FDG PET signal is driven by astroglial glutamate transport
Zimmer, E. R., Parent, M. J., Souza, D. G., Leuzy, A., Lecrux, C., Kim, H.-I., Gauthier, S., Pellerin, L., Hamel, E., & Rosa-Neto, P. (2017) · Nature Neuroscience · doi:10.1038/nn.4492 · Cited by 343
Reduced Glucose Transporter at the Blood‐Brain Barrier and in Cerebral Cortex in Alzheimer Disease
Kalaria, R. N., & Harik, S. I. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb07399.x · Cited by 338 · cited 1×
“For instance, AD patients exhibit lower levels of brain GLUT1 and GLUT3 [177,178], especially in the dentate gyrus of the hippocampus [178] and the cerebral cortex [179], which correlate with decreased brain glucose uptake and cognitive deficits [180].”
BackgroundCraft, S., Claxton, A., Baker, L. D., Hanson, A. J., Cholerton, B., Trittschuh, E. H., Dahl, D., Caulder, E., Neth, B., Montine, T. J., et al. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-161256 · Cited by 335
Brown, A. M. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02421.x · Cited by 308 · cited 5×
“In addition, glycogenolysis has the advantage of producing G6P without ATP consumption and can yield ATP under anaerobic conditions [74,75].”
BackgroundInfluentialA ketogenic diet reduces amyloid beta 40 and 42 in a mouse model of Alzheimer's disease
Van der Auwera, I., Wera, S., Van Leuven, F., & Henderson, S. T. (2005) · Nutrition & Metabolism · doi:10.1186/1743-7075-2-28 · Cited by 307
Cukierman-Yaffe, T., Gerstein, H. C., Colhoun, H. M., Diaz, R., García-Pérez, L.-E., Lakshmanan, M., Bethel, A., Xavier, D., Probstfield, J., Riddle, M. C., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30173-3 · Cited by 300
Luchsinger, J. A., Perez, T., Chang, H., Mehta, P., Steffener, J., Pradabhan, G., Ichise, M., Manly, J., Devanand, D. P., & Bagiella, E. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-150493 · Cited by 285 · cited 2×
“Within this last group of insulin modulator drugs, some of them have shown promising results in the treatment of AD, especially metformin [261,262], thiazolidinediones [263–266], SGLT2 inhibitors [267] and glucose like peptide-1 (GLP-1) analogues [268–272].”
BackgroundSa-nguanmoo, P., Tanajak, P., Kerdphoo, S., Jaiwongkam, T., Pratchayasakul, W., Chattipakorn, N., & Chattipakorn, S. C. (2017) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2017.08.005 · Cited by 274
Hyder, F., Rothman, D. L., & Bennett, M. R. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1214912110 · Cited by 271 · cited 1×
“, astrocytes, oligodendrocytes and microglia [6,8], illustrating that the metabolic signature differs between different brain cells.”
BackgroundBouzier‐Sore, A., Voisin, P., Bouchaud, V., Bezancon, E., Franconi, J., & Pellerin, L. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.05056.x · Cited by 265
Schurr, A., Payne, R. S., Miller, J. J., & Rigor, B. M. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69010423.x · Cited by 262
Nicolakakis, N., Aboulkassim, T., Ongali, B., Lecrux, C., Fernandes, P., Rosa-Neto, P., Tong, X.-K., & Hamel, E. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3348-08.2008 · Cited by 262
Croteau, E., Castellano, C. A., Fortier, M., Bocti, C., Fulop, T., Paquet, N., & Cunnane, S. C. (2018) · Experimental Gerontology · doi:10.1016/j.exger.2017.07.004 · Cited by 258
Uddin, M., Wildman, D. E., Liu, G., Xu, W., Johnson, R. M., Hof, P. R., Kapatos, G., Grossman, L. I., & Goodman, M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308725100 · Cited by 238
Escribano, L., Simón, A.-M., Gimeno, E., Cuadrado-Tejedor, M., López de Maturana, R., García-Osta, A., Ricobaraza, A., Pérez-Mediavilla, A., Del Río, J., & Frechilla, D. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.32 · Cited by 235
Claxton, A., Baker, L. D., Wilkinson, C. W., Trittschuh, E. H., Chapman, D., Watson, G. S., Cholerton, B., Plymate, S. R., Arbuckle, M., & Craft, S. (2013) · Journal of Alzheimer’s Disease · doi:10.3233/jad-122308 · Cited by 215
Mechanisms of Amyloid-β Peptide Clearance: Potential Therapeutic Targets for Alzheimer's Disease
Yoon, S.-S., & AhnJo, S.-M. (2012) · Biomolecules and Therapeutics · doi:10.4062/biomolther.2012.20.3.245 · Cited by 205 · cited 1×
“The degree of Aβ clearance has a great role in its accumulation [138].”
BackgroundThe rat blood-brain barrier transcriptome
Enerson, B. E., & Drewes, L. R. (2006) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600249 · Cited by 205
Glutamate transporter variants reduce glutamate uptake in Alzheimer's disease
Scott, H. A., Gebhardt, F. M., Mitrovic, A. D., Vandenberg, R. J., & Dodd, P. R. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.03.008 · Cited by 202
Accelerated evolution of the electron transport chain in anthropoid primates
Grossman, L. I., Wildman, D. E., Schmidt, T. R., & Goodman, M. (2004) · Trends in Genetics · doi:10.1016/j.tig.2004.09.002 · Cited by 186
Wu, L., Zhang, X., & Zhao, L. (2018) · The Journal of Neuroscience · doi:10.1523/jneurosci.2262-17.2018 · Cited by 185 · cited 1×
“Moreover, at the cellular level, ApoE4 expression in astrocytes induces alterations in glycolysis, glucose uptake and lactate secretion [238,241].”
BackgroundXu, P.-T., Schmechel, D., Rothrock-Christian, T., Burkhart, D. S., Qiu, H.-L., Popko, B., Sullivan, P., Maeda, N., Saunders, A. M., Roses, A. D., et al. (1996) · Neurobiology of Disease · doi:10.1006/nbdi.1996.0023 · Cited by 178
Apolipoprotein E, not fibrillar β-amyloid, reduces cerebral glucose metabolism in normal aging
Jagust, W. J., Landau, S. M., & Initiative, F. T. A. D. N. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.3266-12.2012 · Cited by 162
Protas, H. D., Chen, K., Langbaum, J. B. S., Fleisher, A. S., Alexander, G. E., Lee, W., Bandy, D., de Leon, M. J., Mosconi, L., Buckley, S., et al. (2013) · JAMA Neurology · doi:10.1001/2013.jamaneurol.286 · Cited by 161 · cited 2×
“Indeed, given the role of astrocytes as brain energy suppliers, the observation that progressive perturbations affecting astrocytic metabolism and functionality are associated with the disruption of brain glucose metabolism in AD patients is especially relevant [154].”
BackgroundMolecular Mechanisms of Microglial Motility: Changes in Ageing and Alzheimer’s Disease
Franco-Bocanegra, D. K., McAuley, C., Nicoll, J. A. R., & Boche, D. (2019) · Cells · doi:10.3390/cells8060639 · Cited by 147
Expression of the Na+‐d‐Glucose Cotransporter SGLT1 in Neurons
Poppe, R., Karbach, U., Gambaryan, S., Wiesinger, H., Lutzenburg, M., Kraemer, M., Witte, O. W., & Koepsell, H. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69010084.x · Cited by 134
Pan, Y., & Nicolazzo, J. A. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.04.009 · Cited by 131
Regional distribution of SGLT activity in rat brain in vivo
Yu, A. S., Hirayama, B. A., Timbol, G., Liu, J., Diez-Sampedro, A., Kepe, V., Satyamurthy, N., Huang, S.-C., Wright, E. M., & Barrio, J. R. (2013) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00317.2012 · Cited by 126
Farrer, L. A. (1997) · JAMA · doi:10.1001/jama.1997.03550160069041 · Cited by 124
Metformin attenuates plaque-associated tau pathology and reduces amyloid-β burden in APP/PS1 mice
Chen, Y., Zhao, S., Fan, Z., Li, Z., Zhu, Y., Shen, T., Li, K., Yan, Y., Tian, J., Liu, Z., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00761-9 · Cited by 111
Schallier, A., Smolders, I., Van Dam, D., Loyens, E., De Deyn, P. P., Michotte, A., Michotte, Y., & Massie, A. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-101005 · Cited by 109 · cited 1×
“In a similar manner, another study found decreased expression of EAAT2 protein in the cortex and hippocampus, leading to a drastic alteration of glutamate reuptake activity [193].”
ResultPawlosky, R. J., Kemper, M. F., Kashiwaya, Y., King, M. T., Mattson, M. P., & Veech, R. L. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.13958 · Cited by 108
Microglial mitophagy mitigates neuroinflammation in Alzheimer's disease
Lautrup, S., Lou, G., Aman, Y., Nilsen, H., Tao, J., & Fang, E. F. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.104469 · Cited by 105
APOE alters glucose flux through central carbon pathways in astrocytes
Williams, H. C., Farmer, B. C., Piron, M. A., Walsh, A. E., Bruntz, R. C., Gentry, M. S., Sun, R. C., & Johnson, L. A. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104742 · Cited by 105
Kinetics of arginine-vasopressin uptake at the blood-brain barrier
Zlokovic, B. V., Hyman, S., McComb, J. G., Lipovac, M. N., Tang, G., & Davson, H. (1990) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(90)90097-8 · Cited by 98
Molecular evolution of aerobic energy metabolism in primates.
Grossman, L. I., Schmidt, T. R., Wildman, D. E., & Goodman, M. (2001) · Molecular Phylogenetics and Evolution · doi:10.1006/mpev.2000.0890 · Cited by 86
Repurposed agents in the Alzheimer’s disease drug development pipeline
Bauzon, J., Lee, G., & Cummings, J. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00662-x · Cited by 77 · cited 1×
“obtained by these drugs have shed a bit of light and hope for the development of future AD therapies, current results should be interpreted with caution, as there have been no new drug approvals for the treatment of dementia so far [273,274].”
ResultAmyloid β 1-42 Induces Hypometabolism in Human Stem Cell-Derived Neuron and Astrocyte Networks
Tarczyluk, M. A., Nagel, D. A., Parri, H. R., Tse, E. H., Brown, J. E., Coleman, M. D., & Hill, E. J. (2015) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.58 · Cited by 42
Cited by
Yen, C., Lin, C.-L., & Chiang, M.-C. (2023) · Life · doi:10.3390/life13071472 · Cited by 281
Decoding microglial immunometabolism: a new frontier in Alzheimer's disease research
Jung, E. S., Choi, H., & Mook-Jung, I. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00825-0 · Cited by 124
Kazemeini, S., Nadeem-Tariq, A., Shih, R., Rafanan, J., Ghani, N., & Vida, T. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111720 · Cited by 41
“The resulting energy deficiency affects synaptic function and neuronal survival [107].”
BackgroundInfluentialRegulation of astrocyte metabolism by mitochondrial translocator protein 18 kDa
Firth, W., Robb, J. L., Stewart, D., Pye, K. R., Bamford, R., Oguro‐Ando, A., Beall, C., & Ellacott, K. L. J. (2024) · Journal of Neurochemistry · doi:10.1111/jnc.16089 · Cited by 5
“This is potentially important as the early stages of Alzheimer's disease correlate with a metabolic shift in the brain (Ardanaz et al., 2022 ).”
Background
Metadata
- Authors
- Ardanaz, C. G., Ramírez, M. J., & Solas, M.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-03-29
- Volume
- 23
- Issue
- 7
- Pages
- 3785
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W4220959211
- Cited by
- 125
- References
- 110
- FWCI
- 11.81
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.